568 related articles for article (PubMed ID: 28098353)
1. The role of various peroxisome proliferator-activated receptors and their ligands in clinical practice.
Derosa G; Sahebkar A; Maffioli P
J Cell Physiol; 2018 Jan; 233(1):153-161. PubMed ID: 28098353
[TBL] [Abstract][Full Text] [Related]
2. Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?
Tenenbaum A; Fisman EZ
Cardiovasc Diabetol; 2012 Nov; 11():140. PubMed ID: 23150952
[TBL] [Abstract][Full Text] [Related]
3. Healing the diabetic heart: modulation of cardiometabolic syndrome through peroxisome proliferator activated receptors (PPARs).
Huang TH; Roufogalis BD
Curr Mol Pharmacol; 2012 Jun; 5(2):241-7. PubMed ID: 22122453
[TBL] [Abstract][Full Text] [Related]
4. Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons.
Tenenbaum A; Motro M; Fisman EZ
Cardiovasc Diabetol; 2005 Sep; 4():14. PubMed ID: 16168052
[TBL] [Abstract][Full Text] [Related]
5. The Opportunities and Challenges of Peroxisome Proliferator-Activated Receptors Ligands in Clinical Drug Discovery and Development.
Hong F; Xu P; Zhai Y
Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30060458
[TBL] [Abstract][Full Text] [Related]
6. Comparative Evaluation of Gemcabene and Peroxisome Proliferator-Activated Receptor Ligands in Transcriptional Assays of Peroxisome Proliferator-Activated Receptors: Implication for the Treatment of Hyperlipidemia and Cardiovascular Disease.
Bisgaier CL; Oniciu DC; Srivastava RAK
J Cardiovasc Pharmacol; 2018 Jul; 72(1):3-10. PubMed ID: 29621036
[TBL] [Abstract][Full Text] [Related]
7. Evolution of peroxisome proliferator-activated receptor agonists.
Chang F; Jaber LA; Berlie HD; O'Connell MB
Ann Pharmacother; 2007 Jun; 41(6):973-83. PubMed ID: 17519293
[TBL] [Abstract][Full Text] [Related]
8. The roles of peroxisome proliferator-activated receptors in the metabolic syndrome.
Mansour M
Prog Mol Biol Transl Sci; 2014; 121():217-66. PubMed ID: 24373239
[TBL] [Abstract][Full Text] [Related]
9. Dual acting and pan-PPAR activators as potential anti-diabetic therapies.
Heald M; Cawthorne MA
Handb Exp Pharmacol; 2011; (203):35-51. PubMed ID: 21484566
[TBL] [Abstract][Full Text] [Related]
10. The cardiovascular effects of peroxisome proliferator-activated receptor agonists.
Friedland SN; Leong A; Filion KB; Genest J; Lega IC; Mottillo S; Poirier P; Reoch J; Eisenberg MJ
Am J Med; 2012 Feb; 125(2):126-33. PubMed ID: 22269613
[TBL] [Abstract][Full Text] [Related]
11. The next generation of PPAR drugs: do we have the tools to find them?
Shearer BG; Billin AN
Biochim Biophys Acta; 2007 Aug; 1771(8):1082-93. PubMed ID: 17602866
[TBL] [Abstract][Full Text] [Related]
12. Targeting components of the stress system as potential therapies for the metabolic syndrome: the peroxisome-proliferator-activated receptors.
Yumuk VD
Ann N Y Acad Sci; 2006 Nov; 1083():306-18. PubMed ID: 17148746
[TBL] [Abstract][Full Text] [Related]
13. Safety issues and prospects for future generations of PPAR modulators.
Rubenstrunk A; Hanf R; Hum DW; Fruchart JC; Staels B
Biochim Biophys Acta; 2007 Aug; 1771(8):1065-81. PubMed ID: 17428730
[TBL] [Abstract][Full Text] [Related]
14. Peroxisome Proliferator-Activated Receptor (PPAR) Gamma Agonists as Therapeutic Agents for Cardiovascular Disorders: Focus on Atherosclerosis.
Ivanova EA; Myasoedova VA; Melnichenko AA; Orekhov AN
Curr Pharm Des; 2017; 23(7):1119-1124. PubMed ID: 27855608
[TBL] [Abstract][Full Text] [Related]
15. Peroxisome proliferator-activated receptor (PPAR) in metabolic syndrome and type 2 diabetes mellitus.
Jay MA; Ren J
Curr Diabetes Rev; 2007 Feb; 3(1):33-9. PubMed ID: 18220654
[TBL] [Abstract][Full Text] [Related]
16. Elucidating the Beneficial Role of PPAR Agonists in Cardiac Diseases.
Khuchua Z; Glukhov AI; Strauss AW; Javadov S
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30400386
[TBL] [Abstract][Full Text] [Related]
17. Peroxisome proliferator-activated receptors (PPARs) in the control of bone metabolism.
Giaginis C; Tsantili-Kakoulidou A; Theocharis S
Fundam Clin Pharmacol; 2007 Jun; 21(3):231-44. PubMed ID: 17521292
[TBL] [Abstract][Full Text] [Related]
18. Peroxisome proliferator-activated receptors and atherosclerosis.
Soskić SS; Dobutović BD; Sudar EM; Obradović MM; Nikolić DM; Zarić BL; Stojanović SD; Stokić EJ; Mikhailidis DP; Isenović ER
Angiology; 2011 Oct; 62(7):523-34. PubMed ID: 21467121
[TBL] [Abstract][Full Text] [Related]
19. Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications--a review.
Grygiel-Górniak B
Nutr J; 2014 Feb; 13():17. PubMed ID: 24524207
[TBL] [Abstract][Full Text] [Related]
20. Role of PPAR receptor in different diseases and their ligands: Physiological importance and clinical implications.
Mirza AZ; Althagafi II; Shamshad H
Eur J Med Chem; 2019 Mar; 166():502-513. PubMed ID: 30739829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
